Can Neuroimaging Save Psychedelic Drug Development? Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how neuroimaging technologies like PET, fMRI and multimodal approaches provide objective insights into brain mechanisms of psychedelic therapies. Attendees will gain insight into how imaging biomarkers can validate clinical outcomes, support regulatory submissions and reduce the impact of placebo or expectancy effects. The featured speaker will discuss why neuroimaging is critical for optimizing dosing strategies, patient stratification and trial design in psychedelic drug development. The speaker will also share a practical framework for integrating neuroimaging into preclinical and clinical workflows to accelerate development and improve decision-making.

TORONTO, Oct. 9, 2025 /PRNewswire/ — Psychedelic drug development is advancing quickly, but clinical progress often stalls due to small datasets, regulatory uncertainty and a lack of objective biomarkers. What if neuroimaging could change that, offering a data-driven foundation for more reliable, reproducible development?

This webinar is designed for researchers, clinical developers and investors looking to accelerate psychedelic therapy programs with scientifically grounded insights. Discover how advanced neuroimaging techniques, such as PET and fMRI, and other multimodal approaches, are clarifying mechanisms of action, validating biomarkers and guiding precision dosing and patient stratification.

Join the featured speaker to explore:

• How neuroimaging is uncovering unique neuroplasticity and connectivity effects linked to therapeutic outcomes
• Real-world examples of imaging data informing smarter trial designs and patient selection
• Practical strategies for integrating imaging insights into regulatory submissions and clinical decision-making

Register for this webinar to see how neuroimaging can transform psychedelic drug development, reduce risk, improve study design and help bring safe and effective treatments.

Join Matthew Wall, PhD, Associate Director of Translational MRI, Perceptive, for the live webinar on Monday, October 27, 2025, at 9am EDT (2pm CET/EU-Central). 

For more information or to register for this event, visit Can Neuroimaging Save Psychedelic Drug Development?

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit www.xtalks.com
For information about hosting a webinar, visit www.xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/can-neuroimaging-save-psychedelic-drug-development-upcoming-webinar-hosted-by-xtalks-302579323.html

SOURCE Xtalks